Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 80 |
| Active Pipeline (Recruiting Now) | 28 (18) |
| Completed vs Stopped Early | 33 / 19 (23.8%) |
| Median Closed Actual Enrollment | 32 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Duke University Medical Center | Durham, NC | 53 |
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | 4 |
| Johns Hopkins Hospital and Kimmel Cancer Center | Baltimore, MD | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07232069 | PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis | Phase III | RECRUITING |
| NCT06404086 | RECOVER-SLEEP: Platform Protocol | Phase II | COMPLETED |
| NCT03841357 | Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Duke University Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.